Health
23 Oct 2026
FDA accepts Biohaven’s resubmission for Vyglxia
The FDA has accepted Biohaven’s resubmitted application for Vyglxia, a drug targeting spinocerebellar ataxia, and will hold an advisory committee meeting.
Read moreTopic
#Vyglxia
1 story